このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Dian Diagnostics GroupLtd マネジメント

マネジメント基準チェック /24

Dian Diagnostics GroupLtd'sの CEO はHaibin Chenで、 May2010年に任命され、の在任期間は 14.08年です。は、会社の株式の26.55%を直接所有しており、その価値はCN¥ 2.14B 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と0.6年です。

主要情報

Haibin Chen

最高経営責任者

CN¥3.6m

報酬総額

CEO給与比率	n/a
CEO在任期間	14.2yrs
CEOの所有権	26.5%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Jun 10

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22

CEO（最高経営責任者

Haibin Chen (55 yo)

14.2yrs

在職期間

CN¥3,560,400

報酬

Mr. Haibin Chen,B.S. (EMBA) serves as Chairman of the Board at Dian Diagnostics Group Co. Ltd since May 2010 and serves as its Chief Executive Officer since November 2023. He was the Chairman, General Mana...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Haibin Chen	GM & Chairman of the Board	14.2yrs	CN¥3.56m	26.55% CN¥ 2.0b
Sanhui Guo	Deputy General Manager & Director	5.5yrs	CN¥2.21m	0.015% CN¥ 1.1m
Hanhua Hong	Deputy General Manager & Director	less than a year	CN¥797.00k	データなし
Jun Tao	Deputy GM & Secretary of the Board	3.2yrs	CN¥855.60k	データなし

4.3yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: 300244の経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Haibin Chen	GM & Chairman of the Board	14.2yrs	CN¥3.56m	26.55% CN¥ 2.0b
Sanhui Guo	Deputy General Manager & Director	4.8yrs	CN¥2.21m	0.015% CN¥ 1.1m
Hanhua Hong	Deputy General Manager & Director	less than a year	CN¥797.00k	データなし
Xiaoping Ye	Non-Independent Director	less than a year	データなし	データなし
Tiantian Li	Independent Director	3.8yrs	CN¥120.00k	データなし
Dechao Yu	Non-Independent Director	less than a year	データなし	データなし
Bin Jiang	Independent Director	less than a year	CN¥20.00k	データなし
Zelin Deng	Independent Director	less than a year	データなし	データなし

0.7yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: 300244の取締役会は経験豊富ではない ( 0.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Dian Diagnostics GroupLtd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Less than half of directors are independent

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Board Elations

Recent updates

Dian Diagnostics Group Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to CN¥0.06

Dian Diagnostics Group Co.,Ltd. Announces Dividend on share A for the Year 2023, Payable on June 13, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Price target decreased by 7.5% to CN¥25.72

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.3% to CN¥28.27

Dian Diagnostics Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Price target decreased by 9.9% to CN¥31.56

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 20%

Price target decreased by 8.0% to CN¥37.35

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023

Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022

Price target decreased by 10% to CN¥38.72

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 10%, revenue upgraded

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) announces an Equity Buyback for CNY 50 million worth of its shares.

Less than half of directors are independent

Consensus revenue estimates increase by 14%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Dividend for 2021

Now 20% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Price target decreased to CN¥48.50

Third quarter 2021 earnings released: EPS CN¥0.81 (vs CN¥0.64 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.63 (vs CN¥0.80 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥52.85

Dian Diagnostics Group Co.,Ltd. Approved Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.011 in 1Q 2020)

Consensus EPS estimates increase to CN¥1.82

Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥0.56 in FY 2019)

New 90-day low: CN¥32.92

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥43.96

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥53.63

New 90-day low: CN¥36.20

Analysts update estimates

Third quarter earnings released

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Dian Diagnostics Group Co.,Ltd. Announces Board Elations

Hu Yong and Xu Min completed the acquisition of 10% stake in Zhejiang Di’an Diagnostic Technology Co., Ltd. from Chen Haibin and Lai Cuiying.

Analysts update estimates

Earnings released

Price target raised to CN¥35.41

New 90-day high - CN¥40.49

マネジメント基準チェック /24